Prostate Cancer
Prostate cancer cell line characterization reveals hormone-refractory progression
Published in Gene Therapy Weekly, February 23rd, 2006
"Insights into the molecular basis of hormone-refractory prostate cancer have principally relied on human prostate cancer cell lines, all of which were derived from patients who had already failed hormonal therapy."
"Recent progress in developing genetically engineered mouse prostate cancer models provides an opportunity to isolate novel cell lines front animals never exposed to hormone ablation, avoiding any potential bias conferred by the selective pressure of the castrate environment," wrote P.A. Watson and...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2006-02-23)
More Articles from Gene Therapy Weekly
- Gene Therapy
An siRNA-based microbicide protects mice from lethal HSV-2 infection - Gene Therapy
Electroporation gene transfer does not affect testicular integrity or sperm quality - Gene Therapy
Influenza virus siRNA expression vectors inhibit influenza virus multiplication - Gene Therapy
RNA interference has an antiviral role in Caenorhabditis elegans - Adenocarcinoma
Glycodelin reduces endometrial adenocarcinoma-associated gene expression - Allergy & Immunology
Study describes sequence and gene transfer vector of human adenovirus serotype 3 - More from this issue of Gene Therapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
